Anthropic says its Claude AI models are helping biotechnology companies accelerate several stages of drug development, from reviewing manufacturing documentation to designing experimental antibodies. In one evaluation with biotechnology company Enveda, a Claude-powered system reviewed 1,061 pages of manufacturing records, identified all 11 actionable issues previously found by human reviewers and flagged seven additional issues. The workflow reduced review time by 89%, from 25.9 hours to 2.8 hours.
The findings, published by Anthropic on October 27, 2026, highlight how AI could help pharmaceutical researchers manage complex paperwork, analyze experiments and evaluate potential drug candidates. Other collaborations involved Bristol Myers Squibb, BigHat Biosciences, Divergence Labs and Generate Biomedicines. However, the results come primarily from early-stage research and company-specific evaluations. Human experts continue to verify findings, oversee experiments and make important quality and safety decisions.
Key Takeaways
- 89% less review time: Enveda reduced manufacturing-record review from 25.9 hours to 2.8 hours using a Claude-powered workflow.
- Seven additional issues: Claude flagged seven actionable problems that human reviewers had not identified in the evaluated records.
- Regulatory paperwork: Claude drafted a regulatory document in four hours, compared with approximately three months for manual preparation, according to Anthropic.
- Drug design: Research partners used Claude to develop and evaluate antibody designs and improve experimental drug candidates.
- Human oversight remains essential: Pharmaceutical experts continued reviewing AI outputs and retained responsibility for quality decisions.
- Early-stage evidence: The results do not establish that AI-designed treatments are safe and effective in humans or ready for regulatory approval.
How Claude Reduced Drug Review Time by 89%
One of the biggest administrative challenges in pharmaceutical development is preparing and reviewing the extensive documentation required to manufacture medicines and conduct clinical trials.
Manufacturers must maintain records demonstrating that each batch meets quality requirements. These documents can include production steps, test results, deviations, signatures and other information that reviewers must examine carefully.
Enveda developed a system called the CMC Document Processor, or CDP, that connects manufacturing documentation to Claude. The system considers the relationships between documents, technical requirements and a drug development program’s history to identify potential issues.
Anthropic reported that Enveda evaluated the system using 1,061 pages of batch records from a Phase 2 manufacturing campaign.
| Measurement | Result |
|---|---|
| Manufacturing documentation evaluated | 1,061 pages |
| Actionable issues identified by human reviewers | 11 |
| Human-identified issues also flagged by Claude | All 11 |
| Additional actionable issues flagged by Claude | 7 |
| Manual review time | 25.9 hours |
| AI-assisted review time, including checking findings | 2.8 hours |
| Reported time reduction | 89% |
The additional findings included a manufacturing process step that exceeded its permitted time limit and a test marked as failed without a corresponding recorded result. Enveda’s quality team resolved the identified issues with the manufacturer before the batch was released.
The system also made an error by misreading a handwritten correction. It flagged the interpretation as requiring verification rather than presenting it as certain. This example illustrates why human review remains important even when an AI workflow performs well.
How Claude Found Issues Human Reviewers Missed
The significance of Enveda’s results is not limited to faster document processing. The system also identified issues that had escaped the original human review.
In the evaluated records, the seven additional actionable findings were considered relevant by Enveda’s quality team. These included problems that needed correction or clarification from the manufacturer.
This capability could be valuable because manufacturing documentation is highly technical and often involves relationships between multiple records. A problem may become apparent only when a reviewer compares a process step with a limit, checks whether a failed test has a recorded result or examines whether different documents are consistent.
AI can help by systematically comparing information and highlighting anomalies for closer inspection. It may also reduce the burden on experts who otherwise spend hours reading repetitive documentation.
However, the result should not be interpreted as proof that Claude is consistently better than pharmaceutical professionals. The evaluation involved a particular dataset and workflow, and human reviewers remained responsible for deciding which comments required action. The findings demonstrate a promising use case rather than a universal benchmark for AI accuracy.
Claude Also Speeds Up Regulatory Documentation
Beyond reviewing manufacturing records, Enveda used Claude to prepare first drafts of two important regulatory documents.
According to Anthropic, one document took approximately four hours to draft with AI assistance, compared with around three months using the company’s conventional manual process. Human review of the other document identified one minor error.
Regulatory documentation requires considerable technical detail, consistency and careful alignment with the underlying evidence. AI can assist with organizing information, producing structured drafts and connecting information across large collections of records.
The distinction between drafting and approval is important. A faster first draft does not eliminate the need to verify scientific claims, confirm data accuracy or ensure that the final submission meets regulatory requirements.
Enveda’s experience suggests that appropriately configured AI workflows could reduce administrative bottlenecks, allowing specialists to spend more time on scientific and quality-related work.
How Other Pharmaceutical Companies Are Using Claude
Anthropic’s October 27 announcement described partnerships with six organizations developing medicines. The projects explored different stages of the drug-development process.
| Company | Application | Reported result |
|---|---|---|
| Enveda | Manufacturing documentation and regulatory drafting | 89% reduction in review time |
| Bristol Myers Squibb | Analysis of early-stage clinical-trial plans | Generated an initial assessment from a single prompt |
| BigHat Biosciences | Optimization of antibody fragments | Best candidates bound more than 10 times more tightly than the original leads |
| Divergence Labs | Antibody design for food-allergy research | Generated approximately 35,000 antibody designs in about a month |
| Generate Biomedicines | Design work for a cancer therapy | Produced a proposed gene design about 70% shorter than the standard version |
| The Column Group | Drug-development research collaboration | Included in Anthropic’s broader research partnership program |
These projects address different scientific problems, so their results cannot be compared directly. A faster document review, an improved laboratory measurement and a generated antibody design are distinct achievements with different validation requirements.
The examples nevertheless illustrate how AI is being tested throughout the research process rather than being used only to suggest new molecules.
Can Claude Help Scientists Develop Better Medicines?
At BigHat Biosciences, researchers used Claude alongside laboratory automation to improve two antibody-fragment candidates. The team generated and tested approximately 1,010 variants over about 10 weeks.
Anthropic reported that the strongest versions bound to their targets more than 10 times as tightly as the original candidates. It also reported improvements in stability and resistance to clumping.
At Divergence Labs, Claude helped generate around 35,000 antibody designs in approximately one month for research into a potential treatment for food allergies. Generate Biomedicines also used the model in work on gene designs for a cancer therapy.
These findings show how AI can help researchers explore more design possibilities and connect experimental results with subsequent decisions. But generating a promising candidate is only one step in drug development.
Potential treatments must undergo extensive laboratory testing, safety assessments and clinical trials. A molecule that performs well against a laboratory target may still fail because of toxicity, poor delivery, manufacturing difficulties or insufficient effectiveness in humans.
Anthropic said its work remains largely preclinical, meaning most of the projects have not yet reached the stage of testing the resulting drugs in human trials.
What This Means for the Pharmaceutical Industry
Drug development is expensive and time-consuming, partly because researchers must manage complex scientific experiments alongside extensive quality and regulatory requirements.
AI tools could help reduce some of this burden by reviewing documents, organizing evidence, proposing experimental designs and highlighting potential inconsistencies. The greatest immediate benefits may come from tasks that are repetitive, information-intensive and easy for qualified experts to verify.
For pharmaceutical companies, the business case will depend on more than model performance. They must assess whether AI workflows consistently produce accurate results, integrate with existing systems and meet requirements for data security, traceability and quality assurance.
There is also a need for independent evaluation. The reported results were published by Anthropic and its research partners, so broader adoption will depend on further testing across different companies, documents, drug programs and scientific conditions.
The Bigger Picture
Anthropic’s latest research suggests that AI’s contribution to medicine may extend beyond designing molecules. Administrative work, manufacturing documentation and regulatory preparation can all consume significant resources, and improvements in these areas could help research teams move more efficiently through development.
The most credible near-term opportunity is AI working alongside specialists: handling repetitive analysis, highlighting potential issues and producing drafts while people verify the evidence and retain decision-making authority. If these systems prove reliable across a wider range of programs, they could help pharmaceutical companies use expert time more effectively without lowering quality standards.
FAQs
1. How did Claude reduce drug review time by 89%?
Enveda used a Claude-powered document-review system to examine 1,061 pages of manufacturing records. The workflow reduced review time from 25.9 hours to 2.8 hours, including human checking of the AI’s findings.
2. How many additional issues did Claude identify?
Claude flagged seven additional actionable issues that human reviewers had not identified in the evaluated records. Enveda’s quality team judged that these issues needed attention and worked with the manufacturer to resolve them.
3. Is Claude replacing pharmaceutical reviewers?
No. Human experts continued checking the AI’s findings, and Enveda’s quality department retained responsibility for the final batch-release decision. The system assists reviewers rather than replacing their accountability.
4. Is Claude already discovering medicines that are proven to work in humans?
The reported projects are largely at the preclinical research stage. Improvements in laboratory measurements or candidate designs do not establish that a treatment is safe and effective in people.
5. Which pharmaceutical companies are working with Anthropic?
Anthropic identified six research partners: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group.
Looking Ahead
The next test for AI-assisted drug development will be whether the reported improvements hold up across larger datasets, more organizations and additional stages of research. Pharmaceutical companies will need to validate these workflows carefully, especially when their outputs affect manufacturing quality, regulatory submissions or decisions about clinical trials.
For now, Claude’s work with Enveda offers a measurable example of how AI can reduce a specific administrative burden while surfacing issues for expert review. If similar results can be reproduced in other settings, AI could become a useful part of the pharmaceutical industry’s effort to accelerate development while maintaining rigorous safety and quality controls.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
